Science & Enterprise subscription

Follow us on Twitter

  • A mobile and computer app that alerts older citizens about a class of drugs associated with Alzheimer's disease wil… https://t.co/ayTyKvff5T
    about 12 hours ago
  • New post on Science and Enterprise: Trial to Test App Alerting for Dementia-Linked Drugs https://t.co/N6RksAetEY #Science #Business
    about 12 hours ago
  • First results from a clinical trial show a combination of immunotherapies extends survival among patients with mela… https://t.co/K0InhxLxaA
    about 17 hours ago
  • New post on Science and Enterprise: Trial Shows Immunotherapies Extend Life with Melanoma https://t.co/aJPRxRWQNE #Science #Business
    about 17 hours ago
  • The world's five leading technology enterprises are acquiring more companies and with more money in recent years th… https://t.co/mH9F5msWAY
    about 3 days ago

Please share Science & Enterprise

We’ve Updated Our Privacy Policies (Like Everyone Else)

GDPR graphic

(Gerd Altmann, Pixabay)

26 May 2018. In keeping with the General Data Protection Regulation in Europe that went into effect yesterday, Technology News and Literature, the publisher of Science & Enterprise, updated its policies on privacy and cookies. You can find those policies posted on our web site.

Regular visitors to Science & Enterprise know we report occasionally on data security matters, so we recognize the motivations behind these new rules. Since we conduct no financial transactions on this site nor share any data we may collect, on subscribers, for example, we intend to keep to the spirit as well as the letter of the regulations.

If you have questions or concerns about our privacy measures, feel free to contact me at sciencebusiness @ technewslit . com. Thank you for your continued readership.

*     *     *

Comments are closed.